Skip to content
OpenCapital
Get started

Exagen Inc. XGN Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
——

Other financials

Income statement

See full
Revenue$17.3M+11.7%
Gross profit$10.2M+11.9%
Operating income-$3.4M-1.5%
Net income-$4.0M-5.7%
EPS (diluted)-$0.17+15.0%

Balance sheet

See full
Cash & equivalents$21.7M+90.6%
Total debt$27.1M+15.8%
Total equity$14.4M+125%
Total assets$52.0M+28.9%

Cash flow

See full
Operating cash flow-$10.4M+2.4%
CapEx$228.0K+102%
Free cash flow-$10.6M+1.3%

Valuation

See full
Market cap$112.34M-26.5%
Enterprise value$117.78M-20.3%
P/S1.6×-1.0×

Profitability

See full
Gross margin58.3%-1.0pp
Operating margin-20.6%-2.9pp
Net margin-29.5%+2.5pp
FCF margin-27.5%—

Returns & leverage

See full
Return on equity-193.6%+355pp
Debt / equity1.9×-1.8×
Current ratio3.5×+1.1×

Where this comes from

Reported directly by Exagen Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue.

The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exagen Inc.'s share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exagen Inc.'s share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value?
Exagen Inc. (XGN) reported share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value of $179K in Q1 2026.
How has Exagen Inc.'s share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value changed year-over-year?
Exagen Inc.'s share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value decreased by 30.1% year-over-year, from $256K to $179K.
What is the long-term trend for Exagen Inc.'s share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value?
Over 5 years (2020 to 2025), Exagen Inc.'s share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value has grown at a -28.8% compound annual growth rate (CAGR), from $3.36M to $617K.